Cargando…

Biomarkers for tyrosine kinase inhibitors in renal cell cancer

Detalles Bibliográficos
Autores principales:	Coupe, Nicholas, Harrison, Michelle, Chua, Wei, de Souza, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708154/ https://www.ncbi.nlm.nih.gov/pubmed/26816714 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.10.01

Ejemplares similares

Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
por: Cho, Daniel C
Publicado: (2013)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
por: Puisset, Florent, et al.
Publicado: (2023)

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
por: Aparicio, L. M. A., et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
por: Michaelis, Jakob, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
por: Dervisis, Nikolaos, et al.
Publicado: (2016)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
por: Sekino, Yohei, et al.
Publicado: (2022)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Dose adjustment for tyrosine kinase inhibitors in non-small cell lung cancer patients with hepatic or renal function impairment
por: Zhao, Dehua, et al.
Publicado: (2021)

Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Wang, Zhaojuan, et al.
Publicado: (2023)

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)

Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
por: Roesler, Rafael, et al.
Publicado: (2021)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
por: Zhang, Hailiang, et al.
Publicado: (2023)

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
por: Poliaková, Michaela, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
por: Russo, Eleonora, et al.
Publicado: (2021)

The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors
por: White, Jasmine Cassar, et al.
Publicado: (2019)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Wang, Li, et al.
Publicado: (2021)

Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma
por: Franczyk, Beata, et al.
Publicado: (2023)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors
por: Tahiri, Andliena, et al.
Publicado: (2022)

Tyrosine kinase – Role and significance in Cancer
por: Paul, Manash K., et al.
Publicado: (2004)

Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis
por: Liu, Feng, et al.
Publicado: (2016)

Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
por: Tan, Bee Kim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c8d7u7id3gv94kjj9kqon7qdaj